Study details
Enrolling now
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
Philip Morris Products S.A.
NCT IDNCT07108166ClinicalTrials.gov data as of Apr 2026
Target enrollment
290
Study length
about 1.7 years
Ages
40+
Locations
44 sites in FL, GA, TX
About this study
Researchers are testing whether switching from cigarette smoking to a treatment called THS improves symptoms like cough frequency and shortness of breath, as well as lung function, in people with COPD and chronic bronchitis. The trial will last for 607 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Cigarette
- 2.THS
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Changes in lung function (from Baseline in FEV1 post-bronchodilator), Changes in the Cough Quality of Life Questionnaire (CQLQ) on chronic cough
Body systems
Respiratory